Analytical Data
-
基因名
PVRIG
-
简介
The PVRIG protein functions as a cell surface receptor for NECTIN2 and may serve as a co-inhibitory receptor capable of inhibiting T-cell receptor-mediated signaling. Upon interaction with NECTIN2, PVRIG inhibits T cell proliferation, suggesting its potential role in regulating immune responses. PVRIG Protein, Human (HEK293, Fc) is the recombinant human-derived PVRIG protein, expressed by HEK293 , with C-hFc labeled tag.
- Application
-
别名
C7orf15; CD112R; PVRIG; transmembrane protein PVRIG; C7orf15MGC138295; MGC104322; MGC138297; MGC2463
-
种属
Human
-
表达系统
HEK293
-
标签
C-hFc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q6DKI7
-
表达区间
T41-D171
-
蛋白长度
Partial
-
分子量
45-50 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PVRIG (programmed death receptor 1 ligand) is recognized as an important immunomodulatory protein that plays a critical role in regulating immune responses, particularly in the context of cancer and chronic infections. As a member of the B7 family of proteins, PVRIG interacts with its receptor, promoting inhibitory signals that can dampen T-cell activation and proliferation. This mechanism of action is particularly significant as it presents a novel target for cancer immunotherapy, where enhancing T-cell responses is crucial for effective tumor rejection. Recent studies have indicated that PVRIG expression is upregulated in various tumors, suggesting its potential role in immune evasion by cancer cells. Consequently, the research surrounding PVRIG has garnered attention for its implications in developing therapeutic strategies aimed at blocking its inhibitory signaling pathways, thereby reinvigorating T-cell function in the tumor microenvironment. Furthermore, understanding the structural characteristics and functional dynamics of PVRIG through recombinant protein studies could pave the way for the design of innovative drugs and combination therapies that enhance immune responses against cancer, making PVRIG an appealing target for future research and clinical applications.
